Chimerix, Inc. (CMRX)
Pre-market:
| Previous close | 1.0100 |
| Open | 1.0100 |
| Bid | 0.9700 x 1300 |
| Ask | 0.9960 x 900 |
| Day's range | 0.9601 - 1.0200 |
| 52-week range | 0.9200 - 2.4000 |
| Volume | |
| Avg. volume | 673,735 |
| Market cap | 85.926M |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | 0.51 |
| EPS (TTM) | 1.9200 |
| Earnings date | 01 Nov 2023 - 06 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireChimerix to Participate in Upcoming Investor Conferences
DURHAM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that management will participate in two upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference in New York City. Mike Andriole, Chief Executive Officer, will present a corporate overview on September 12, 2023 at 9:00 a.m. ET. A l
- GlobeNewswire
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts Key Metabolic and Epigenetic Pathways DURHAM, N.C., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the publication of data in
ZacksChimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
Chimerix (CMRX) delivered earnings and revenue surprises of 8.70% and 95.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
